ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
POSTED
10-07-22
ViiV Healthcare Announces Recipients of Largest Philanthropic Fund in the US Dedicated to HIV Prevention for Black Women
POSTED
08-09-22
ViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox Emergency Response Fund in the US
POSTED
02-25-21
ViiV Healthcare Builds on Accelerate Initiative, Extending Community-Centered Approach Nationally to Disrupt Disparities in Care for Black Same-Gender-Loving Men Living With HIV
POSTED
09-05-17
ViiV Healthcare Awards $1 Million in Grants for Positive Action for Women in the U.S.
ViiV Healthcare announced $1 million in grants for Positive Action for Women (PAFW), a pilot initiative that supports innovative, forward-thinking community collaborations that break down...
POSTED
08-10-17
ViiV Healthcare Expands U.S. Commitment to Youth Living With HIV Through Its Positive Action Program
ViiV Healthcare announced today it will award six new grants designed to help improve the lives of young people living with HIV through its Positive Action for Youth program. The program, which builds on ViiV Healthcare’s ongoing youth-focused programming and outreach, is a two-year, $1 ...
POSTED
04-25-16
ViiV Healthcare étend son accord de brevets pour le dolutégravir auMedicines Patent Pool (MPP), de facon acouvrir tous les pays de la tranche inférieure des revenus intermédiaires.
ViiV Healthcare, socieÌteÌ mondiale speÌcialiseÌe dans le traitement du VIH, controÌ‚leÌe par GSK, et comptant Pfizer Inc. et Shionogi Limited parmi ses actionnaires, a annonceÌ aujourd'hui son intention d’eÌtendre la porteÌe mondiale de son accord de licences nationales concernant ...
POSTED
04-25-16
ViiV Healthcare Extends Medicines Patent Pool Licence Agreement for Dolutegravir to Cover All Lower Middle-Income Countries
ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced an extension of overall country coverage of its existing licence agreement for adults formulation of dolutegravir to the Medicines Patent Pool (MPP) to co...
POSTED
11-20-15
ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern U.S.
ViiV Healthcare today announced it will award seven grants to organizations across the Southern U.S., a community disproportionately impacted by HIV, as part of its
POSTED
11-02-15
ViiV Healthcare Awards Innovative Grants for HIV Programs Focused on MSM Youth
ViiV Healthcare today announced it will award grants to five organizations across the country as part of the Positive Action MSM Youth Engagement Initiative. These grants focus on youth-led social and digital communications solutions to help increase sexual health knowledge, reduce stigma and lin...
POSTED
03-31-15
ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations
ViiV Healthcare today announced the launch of a new initiative designed to support and inform the global effort to alleviate the impact of HIV and AIDS among men who have sex with men (MSM) and transgender populations around the world. Through Positive Action, ViiV Healthcare has committed to inv...
